Index reshuffle puts Zenas BioPharma in growth-focused benchmarks

Zenas BioPharma (ZBIO) has been reclassified across several Russell indexes, moving into multiple growth benchmarks while being removed from various value indexes. This shift can affect investor flows through index fund rebalancing.

The index reshuffle comes after a sharp shift in momentum for Zenas BioPharma, with the stock posting a 1 month share price return of 58.44% and a 1 year total shareholder return of 177.63%, despite a year to date share price decline of 19.77% from recent levels around $27.68.

If this kind of index driven move has you looking beyond a single stock, it may be a suitable moment to widen your search using the 40 healthcare AI stocks.

Zenas BioPharma now sits in growth indexes with a rapid recent share price move and a clinical stage pipeline, but that does not automatically make the stock a bargain. How does the current valuation really stack up?

Preferred price-to-book multiple of 5.2x: Is it justified for Zenas BioPharma?

For Zenas BioPharma, the clearest valuation reference point available is its price to book ratio, which sits at 5.2x against peers and recent trading around $27.68.

The P/B multiple compares the market value of the equity to the book value on the balance sheet, which is often used for companies that are loss making or have limited current revenue. In this case, Zenas BioPharma is currently unprofitable, has reported no revenue and carries a reported loss of $425.151m, so book value and the assets behind the immunology pipeline take on extra importance for investors trying to anchor valuation.

On both measures provided, the stock is described as expensive relative to benchmarks. Zenas BioPharma trades at a P/B of 5.2x compared with a peer average of 3.4x and a broader US biotechs industry average of 2.8x. This indicates that the market is assigning a higher valuation to each dollar of net assets than it does to many comparable companies, even though the company is forecast to remain unprofitable over the next three years.

In other words, the multiple is materially higher than both direct peers and the wider industry. Any investment case therefore has to be comfortable with paying a premium to those reference points in exchange for the company’s clinical stage profile and forecast revenue growth.

Result: Price-to-book of 5.2x (OVERVALUED)

However, Zenas BioPharma’s premium P/B, lack of current revenue and clinical stage focus mean that trial outcomes or funding conditions could quickly challenge this growth driven narrative.

Next Steps

With sentiment clearly mixed around Zenas BioPharma, are you ready to move fast and stress test the story against the data yourself? Take a closer look at the 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond Zenas BioPharma?

Once you have formed a view on Zenas BioPharma, do not stop there. The broader market still holds plenty of opportunities worth reviewing side by side.

• Zero in on potential hidden bargains by scanning the 45 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them.
• Prioritise resilience by reviewing the 74 resilient stocks with low risk scores that pair steadier risk profiles with more robust financial characteristics.
• Stay ahead of the crowd by checking the screener containing 18 high quality undiscovered gems that have strong underlying metrics yet receive far less attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.